orcabio

Our mission is to deliver a cure without compromise for patients through high-precision cell therapies.



About Orca Bio

Orca Bio is a late-stage biotechnology company engineering high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Today, we're focused on developing novel cell therapies for patients with the goal of providing significantly better outcomes with dramatically fewer toxicities than the standard of care.

Since our founding, Orca Bio's leadership team has delivered on its mission, swiftly advancing our pipeline of investigational products from their foundational science into the clinic.

Redefining Cell Therapy Through the Power of Precision

When treating hematological malignancies, physicians are often faced with compromising between the risk of relapse and the risk of serious toxicities, all of which can impact overall patient survival. Our investigational cell therapies are designed to safely replace a patient's diseased blood and immune system with a healthy one with the goal of both curing the disease and reducing serious risks. Our first application is in hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), where there remains a dire unmet need.

Orca Bio's lead investigational cell therapy, Orca-T, is designed to improve outcomes for patients with blood cancer while lowering their risks of developing serious mortality risks. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a pivotal, randomized Phase 3 clinical trial called Precision-T.

Orca Bio's Unique Approach

Orca Bio's platform uses single-cell precision to create proprietary, uniquely-defined products that have the potential to transform allogeneic cell therapy. We have developed a suite of manufacturing technologies that enable unprecedented precision, allowing us to characterize and select each cell included in our products. We leverage highly purified regulatory T cells which are able to sculpt the constituting immune system and build an immuno-regulatory environment that controls for serious complications that can lead to non-relapse mortality, while enabling a potent anti-cancer effect.

FAST FACTS

Year Founded
2016

Locations
Menlo Park, CA (Headquarters)
Sacramento, CA (Manufacturing Facilities)

Number of Employees
100+

Number of Patients Treated in Clinical Trials
400+

Privately Funded
More than $300M in Series A-D

Orca Bio has built its own centralized manufacturing platform to ensure consistent and reliable delivery of our high-precision cell therapies at scale. Importantly, we have consistently achieved donor to patient vein-to-vein turnaround times of less than 72 hours across our ongoing clinical trials.

We believe this is only the beginning. We are advancing our next-generation programs to expand our pipeline to bring cell therapy to all patients who could benefit, including potential application in autoimmune disease and genetic disorders.

Orca Bio Partners with Leading Treatment Centers

Working with leading institutions and top transplant centers, we have taken a rigorous approach to the design and implementation of our clinical trial programs.

- City of Hope
- Memorial Sloan Kettering Cancer Center
- University of Texas MD Anderson Cancer Center
- Weill Cornell Medicine – New York-Presbyterian Hospital
- Moffitt Cancer Center
- Stanford Health Care
- University of Chicago Medical Center
- Sarah Cannon Research Institute
- Ohio State University
- Ronald Reagan UCLA Medical Center